Julius Knowles, Director at Keros Therapeutics, Inc. (KROS), sold 30,907 shares at $50.80 ($1.5M) on 2021-06-07, disclosed to the SEC on 2021-06-08.
Open-market sale of $1.5M KROS by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $47.23 | 2,988 | $141K | 9.3% |
| 2 | $47.23 | 2,988 | $141K | 9.3% |
| 3 | $47.23 | 1,950 | $92K | 6.1% |
| 4 | $47.23 | 1,950 | $92K | 6.1% |
| 5 | $48.15 | 1,018 | $49K | 3.2% |
| 6 | $48.15 | 663 |
| $32K |
| 2.1% |
| 7 | $46.48 | 703 | $33K | 2.2% |
| 8 | $46.48 | 459 | $21K | 1.4% |
| 9 | $47.34 | 786 | $37K | 2.4% |
| 10 | $47.34 | 512 | $24K | 1.6% |
| 11 | $48.76 | 560 | $27K | 1.8% |
| 12 | $48.76 | 366 | $18K | 1.2% |
| 13 | $50.02 | 568 | $28K | 1.9% |
| 14 | $50.02 | 870 | $44K | 2.9% |
| 15 | $50.80 | 3,968 | $202K | 13.3% |
| 16 | $50.80 | 2,586 | $131K | 8.6% |
| 17 | $50.80 | 2,586 | $131K | 8.6% |
| 18 | $50.80 | 3,968 | $202K | 13.3% |
| 19 | $51.46 | 858 | $44K | 2.9% |
| 20 | $51.46 | 560 | $29K | 1.9% |
| Total | $49.14 avg | 30,907 | $1.5M | 100% |
| Filing → |
| KROS | SELL | 2022-01-05 | $5.3M | — | Filing → |
| KROS | SELL | 2021-12-03 | $5.1M | — | Filing → |
| KROS | SELL | 2021-11-03 | $3.9M | — | Filing → |